Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 2331 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis
J. R. Curtis¹, H. Schulze-Koops², L Takiya³, C. A. Mebus⁴, K. Terry⁴, R. Chew⁴ and T. V. Jones³, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Munich, Munich, Germany, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The clinical development program for tofacitinib in RA enrolled ˃500…
Abstract Number: 444 • 2013 ACR/ARHP Annual Meeting
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
M. C. Genovese¹, T. Kawabata², K. Soma², S. Menon², J.D. Clark³, J. Hodge⁴, L. Takiya⁴, R. Riese² and S. Krishnaswami⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). It has a short pharmacokinetic (PK) half-life of…
Abstract Number: 2333 • 2013 ACR/ARHP Annual Meeting
Association Of Mean Changes In Laboratory Safety Parameters With C-Reactive Protein At Baseline and Week 12 In Rheumatoid Arthritis Patients Treated With Tofacitinib
V. Strand¹, J. D. Isaacs², S. Menon³, J. Beal⁴, C. I. Nduaka⁵, S. Krishnaswami³, R. Riese⁵ and M.G. Boy⁵, ¹Stanford University, Palo Alto, CA, ²Newcastle University, Newcastle-upon-Tyne, United Kingdom, ³Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Changes in laboratory parameters observed during tofacitinib treatment…
Abstract Number: 445 • 2013 ACR/ARHP Annual Meeting
Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib
J. J. Gomez-Reino¹, A. Hazra², C. Fosser², S. Menon³, S. H. Zwillich², R. Riese² and S. Krishnaswami³, ¹Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Pfizer Inc, Groton, CT, ³Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Serious infections (requiring hospitalization or parenteral antibiotics; SIEs)…
Abstract Number: 2334 • 2013 ACR/ARHP Annual Meeting
ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
V. Strand¹, D. van der Heijde², C. a. F. Zerbini³, C. A. Connell⁴, D. Gruben⁴, R. Riese⁴ and G. Wallenstein⁴, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy, inhibition of structural damage, and safety of tofacitinib…
Abstract Number: 439 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
E. B. Lee¹, J. R. Curtis², R. Riese³, C. A. Connell³, R. Chew³, M.G. Boy³, E. Maller⁴, C. Su⁴ and L. Wang³, ¹Seoul National University, Seoul, South Korea, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This analysis aimed to describe and…
Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Ketti K. Terry⁴, Hiroyuki Nakamura⁵, Yukako Ohno⁵, David Gruben⁴, Birgitta Benda⁶, Lisy Wang⁴ and Richard Riese⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: L3 • 2013 ACR/ARHP Annual Meeting
A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
MC Genovese¹, Ronald van Vollenhoven², Bradley J. Bloom³, John G. Jiang³ and Nils Kinnman⁴, ¹Stanford University, Palo Alto, CA, ²Karolinska Institute, Stockholm, Sweden, ³Vertex Pharmaceuticals Incorporated, Cambridge, MA, ⁴Vertex Pharmaceuticals Incorporated, Eysins, Switzerland
Background/Purpose: VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). The objective of this 24-week, randomized, placebo-controlled, double-blind,…
Abstract Number: 2329 • 2013 ACR/ARHP Annual Meeting
Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From 3 Randomized Phase 3 Trials
V. Strand¹, R. E. Alten², C. I. Nduaka³, R. Riese³, D. Gruben³, S. H. Zwillich³, J. Andrews³ and G. Wallenstein³, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). RA affects all domains of health-related quality of…
Abstract Number: 2330 • 2013 ACR/ARHP Annual Meeting
Relationship Between Lymphocyte Count and Risk Of Infection In Rheumatoid Arthritis Patients Treated With Tofacitinib
R. F. van Vollenhoven¹, R. Riese², S. Krishnaswami², T. Kawabata², C. Fosser², S. Rottinghaus², M. Lamba² and S. H. Zwillich², ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines involved in lymphocyte development, function and homeostasis…
Abstract Number: 1794 • 2013 ACR/ARHP Annual Meeting
The Jak Inihibitor Tofacitinib Suppresses Synovial Jak-Stat Signalling In Rheumatoid Arthritis
D. L Boyle¹, N. Wei², A. K. Singhal³, D. R. Mandel⁴, P Mease⁵, A. Kavanaugh⁶, R. Shurmur⁷, J. Hodge⁸, Z. Luo⁹, S. Krishnaswami¹⁰, D. Gruben⁹, S. H. Zwillich⁹, K. Soma⁹, J. D. Bradley⁹ and G. S. Firestein¹¹, ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²Arthritis Treatment Center, Frederick, MD, ³Southwest Rheumatology Research LLC, Mesquite, TX, ⁴Office of David R Mandel MD, Inc., Mayfield Village, OH, ⁵Seattle Rheumatology Associates, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA, ⁷Associated Internal Medicine Specialists, Battle Creek, MI, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Groton, CT, ¹⁰Clinical Pharmacology, Pfizer Inc, Groton, CT, ¹¹Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The specific JAK-STAT (signal transducer and activator of…
Abstract Number: 1796 • 2013 ACR/ARHP Annual Meeting
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Yoshiya Tanaka¹, Kahaku Emoto², Mika Tsujimoto², Douglas E. Schlichting³ and William Macias³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Eli Lilly Japan K.K., Kobe, Japan, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 12-week blinded phase…
Abstract Number: 1797 • 2013 ACR/ARHP Annual Meeting
A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis
Monica Luchi, Rosanne Fidelus-Gort, Diane Douglas, Haifeng Zhang, Robert Flores, Robert Newton, Peggy Scherle, Swamy Yeleswaram, Xuejun Chen and Victor Sandor, Incyte Corporation, Wilmington, DE
Background/Purpose: To characterize the safety and efficacy of INCB039110, a novel and selective JAK1 inhibitor, in patients with active RA. Methods: This phase 2, multicenter…
Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting
The STAT1 Signaling Pathway In Giant Cell Arteritis
Bjorn Hartmann¹, Joyce Liao², Michael H. Weisman³, Kenneth J. Warrington⁴, Jorg J. Goronzy¹ and Cornelia M. Weyand⁵, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, ³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…
Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Edward Keystone¹, MC Genovese², Peter Taylor³, Baojin Zhu⁴, Scott D. Beattie⁴, Stephanie de Bono⁴, Terence Rooney⁴, Douglas E. Schlichting⁴ and William Macias⁴, ¹University of Toronto, Toronto, ON, Canada, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].